GlaxoSmithKline and Merck announced today that they have entered into an agreement for over-the-counter (OTC) marketing rights for MEVACOR® (lovastatin).
Under the agreement, GSK will have exclusive rights to market non-prescription MEVACOR in the United States.
Terms of the agreement are confidential but include milestone and royalty payments from GSK to Merck.
More
No comments:
Post a Comment